These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 11490541

  • 1. [Pleuropneumopathy caused by bromocriptine in a patient with Parkinson disease. Review of the literature apropos of a new case].
    Debove P, Simon F, Vaylet F, Renard JL, L'Her P.
    Ann Med Interne (Paris); 1998 Apr; 149(3):167-71. PubMed ID: 11490541
    [Abstract] [Full Text] [Related]

  • 2. [Diffuse interstitial lung disease without pleural involvement and high-dose bromocriptine].
    Marsaudon E, Castet D, Barrault MF, Allais C.
    Rev Mal Respir; 1997 Nov; 14(5):405-7. PubMed ID: 9480488
    [Abstract] [Full Text] [Related]

  • 3. [Bromocriptine in Parkinson's disease: pleuropulmonary toxicity].
    Douvier JJ, Vergeret J, Taytard A, Brottier E, Domblides P, Dubos F, Freour P.
    Ann Med Interne (Paris); 1985 Nov; 136(5):416-8. PubMed ID: 4062141
    [Abstract] [Full Text] [Related]

  • 4. [Pleural effusion induced by bromocriptine].
    Diot E, Diot P, Le Rolland A, Jonville AP, Lasfargues G, Lemarie E, Lavandier M, Guilmot JL.
    Rev Mal Respir; 1990 Nov; 7(2):175-7. PubMed ID: 2320790
    [Abstract] [Full Text] [Related]

  • 5. Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease.
    McElvaney NG, Wilcox PG, Churg A, Fleetham JA.
    Arch Intern Med; 1988 Oct; 148(10):2231-6. PubMed ID: 3178380
    [Abstract] [Full Text] [Related]

  • 6. [Bromocriptine-induced pleuropneumopathy].
    Schmid PA, Suter T, Speich R, Eberli F, Greminger P.
    Dtsch Med Wochenschr; 1994 Nov 11; 119(45):1543-6. PubMed ID: 7956789
    [Abstract] [Full Text] [Related]

  • 7. Pleural disease during treatment with bromocriptine in patients previously exposed to asbestos.
    Hillerdal G, Lee J, Blomkvist A, Rask-Andersen A, Uddenfeldt M, Koyi H, Rasmussen E.
    Eur Respir J; 1997 Dec 11; 10(12):2711-5. PubMed ID: 9493648
    [Abstract] [Full Text] [Related]

  • 8. [Pleuropulmonary fibrosis and bromocriptine].
    Vergeret J, Barat M, Taytard A, Bellvert P, Domblides P, Douvier JJ, Fréour P.
    Sem Hop; 1984 Mar 08; 60(11):741-4. PubMed ID: 6324351
    [Abstract] [Full Text] [Related]

  • 9. [Severe pleuropericarditis induced by long-term bromocriptin therapy, report of a case and review of the literature].
    Ciubotaru V, Poinsignon Y, Brunet-Bourgin F, Mestassi M, Rosenbaum D.
    Rev Med Interne; 2004 Apr 08; 25(4):310-4. PubMed ID: 15050800
    [Abstract] [Full Text] [Related]

  • 10. Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease.
    Todman DH, Oliver WA, Edwards RL.
    Clin Exp Neurol; 1990 Apr 08; 27():79-82. PubMed ID: 2129961
    [Abstract] [Full Text] [Related]

  • 11. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.
    Tintner R, Manian P, Gauthier P, Jankovic J.
    Arch Neurol; 2005 Aug 08; 62(8):1290-5. PubMed ID: 16087771
    [Abstract] [Full Text] [Related]

  • 12. Pleural effusion during bromocriptine exposure in two patients with pre-existing asbestos pleural plaques: a relationship?
    Knoop C, Mairesse M, Lenclud C, Gevenois PA, De Vuyst P.
    Eur Respir J; 1997 Dec 08; 10(12):2898-901. PubMed ID: 9493681
    [Abstract] [Full Text] [Related]

  • 13. Chronic constrictive pericarditis induced by long-term bromocriptine therapy: report of two cases.
    Champagne S, Coste E, Peyrière H, Nigond J, Mania E, Pons M, Hillaire-Buys D, Balmes P, Blayac JP, Davy JM.
    Ann Pharmacother; 1999 Oct 08; 33(10):1050-4. PubMed ID: 10534217
    [Abstract] [Full Text] [Related]

  • 14. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
    Grosset K, Needleman F, Macphee G, Grosset D.
    Mov Disord; 2004 Nov 08; 19(11):1370-4. PubMed ID: 15389984
    [Abstract] [Full Text] [Related]

  • 15. Suggestive evidence for bromocriptine-induced pleurisy.
    Klaassen RJ, Troost RJ, Verhoeven GT, Krepel HP, van der Lely AJ.
    Neth J Med; 1996 Jun 08; 48(6):232-6. PubMed ID: 8710045
    [Abstract] [Full Text] [Related]

  • 16. Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease.
    Townsend M, MacIver DH.
    Heart; 2004 Aug 08; 90(8):e47. PubMed ID: 15253989
    [Abstract] [Full Text] [Related]

  • 17. [Bromocriptine and pulmonary responses].
    Kinnunen E, Viljanen A.
    Duodecim; 1989 Aug 08; 105(19):1614-7. PubMed ID: 2806146
    [No Abstract] [Full Text] [Related]

  • 18. [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine].
    Montastruc JL, Schmitt L, Bagheri H.
    Rev Neurol (Paris); 2003 Apr 08; 159(4):441-3. PubMed ID: 12773874
    [Abstract] [Full Text] [Related]

  • 19. Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson's disease.
    Lancet; 1981 Jan 03; 1(8210):44-5. PubMed ID: 6109080
    [No Abstract] [Full Text] [Related]

  • 20. Bromocriptine and pleuropulmonary disease.
    Melmed S, Braunstein GD.
    Arch Intern Med; 1989 Feb 03; 149(2):258-9. PubMed ID: 2916870
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.